Exchange: NASDAQ
-1.97% $13.95
America/New_York / 25 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 27.59 mill |
EPS: | 0 |
P/E: | 0 |
Earnings Date: | N/A |
SharesOutstanding: | 1.978 mill |
Avg Daily Volume: | 0.0384 mill |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE 0 | sector: PE 14.70 |
PE RATIO: COMPANY / INDUSTRY |
---|
N/A |
Company: PE 0 | industry: PE 17.27 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 13.46 - 14.44 ( +/- 3.53%) |
ATR Model: 14 days |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $13.95 (-1.97% ) |
Volume | 0.0064 mill |
Avg. Vol. | 0.0384 mill |
% of Avg. Vol | 16.56 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. At least 80% of its total assets will be invested in the component securities of the index. The fund is non-diversified.